| Business Summary | | IOMED,
Inc.
is
a
specialty
pharmaceutical
company
focused
on
satisfying
substantial
unmet
medical
needs
in
large
pharmaceutical
markets.
The
Company
is
currently
pursuing
research,
product
development
and
commercialization
activities
in
the
local
inflammation
and
ophthalmic
markets.
The
Company
is
funded,
in
part,
by
an
established
business
engaged
in
the
manufacture
and
sale
of
iontophoretic
drug
delivery
systems
primarily
used
to
treat
acute
local
inflammation
in
the
sports
and
occupational
medicine
and
physical
therapy
markets.
The
Company
currently
markets
an
iontophoretic
product
to
the
physical
therapy
market
used
to
deliver
a
potent
corticosteriod.
Using
this
product,
over
13
million
treatments
have
been
clinically
administered
to
treat
inflammation.
The
Company
is
also
developing
products
in
other
therapeutic
areas,
including
ophthalmic
disease
and
pain
control. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IOX
is
a
specialty
pharmaceutical
company
that
is
pursuing
research,
product
development,
and
commercialization
activities
in
the
local
inflamation
and
opthalmic
markets;
it
currently
markets
an
iontophoretic
product
to
the
physical
therapy
market.
For
the
nine
months
ended
3/31/01,
revenues
rose
7%
to
$8.4
million.
Net
loss
totaled
$4.1
million,
up
from
$479
thousand.
Results
reflect
growth
in
the
IOGEL
product
line,
offset
by
higher
development
programs
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Peter Wardle, 65 Chairman | -- | James Weersing, 61 Pres
and CEO, Director | $290K | Robert Lollini, 46 Exec.
VP-Fin., CFO, Sec. | 205K | Steven Hamilton, 49 Exec.
VP, Bus. Devel. | 196K | W. Tim Miller, 49 Exec.
VP, IOMED Clinical Systems | 219K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|